Organogenesis Expands with New Biomanufacturing Facility

By Tamara Parker • Saturday, November 23 10:21 • Permanent Link

Organogenesis Holdings Inc. (NASDAQ: ORGO) has announced its plans to expand manufacturing capacity with the lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. This move is aimed at supporting future growth for the company.

Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board, expressed the company's enthusiasm in joining the Rhode Island life sciences community and expanding their New England manufacturing capacity. The company aims to strengthen its industry-leading portfolio with this new biomanufacturing facility.

Organogenesis Holdings Inc. will continue to operate its headquarters and manufacturing facilities in Canton, Mass., as well as additional operations in Norwood, Mass., Birmingham, Ala., San Diego, Calif., St. Petersburg, Fla., and Reinach, Switzerland. It's important to note that the Rhode Island lease is contingent upon anticipated state and local tax incentives.

This strategic expansion signals the company's commitment to scaling up its manufacturing capabilities to facilitate future growth and underscores its dedication to innovation and excellence within the regenerative medicine industry. Today the company's shares have moved 0.7% to a price of $4.05. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.